Abraxane® is also known as nab-paclitaxelIntravenous Chemotherapy

Abraxane® is usually given in conjunction with gemcitabine for advanced pancreatic cancer by intravenous infusion (through a drip) with each infusion usually lasting around 30 minutes. You will often be given anti-sickness drugs (anti-emetics) at the same time.

Intravenous infusions are given through a thin, short tube (cannula) put into a vein in your arm each time you have treatment.

Alternatively, you may have a central line, a portacath or a PICC line inserted just before your treatment starts. These are tubes that give the drugs directly into a large vein in your chest and will stay in place as long as you need them.

Abraxane® (also known as nab-paclitaxel) it has been used in combination with gemcitabine within clinical trials and a recent phase III randomised trial showed that nab-pactlitaxel plus gemcitabine was superior to gemcitabine alone.

It is hoped there will be a licence to use Abraxane® in the UK for metastatic (spread to other parts of the body) pancreatic cancer by the end of 2013. In the meantime, some oncologists in the UK will offer this to patients with advanced disease if there is approval from local commissioners.

 Side effects of Abraxane® are known to be:

The most common side effects of Abraxane® include:

 Infections can be serious. Let your doctor or nurse know immediately if your temperature goes above 38o (100.4o F) or you suddenly feel unwell even with a normal temperature.

Click here to read about other chemotherapy drugs for pancreatic cancer.